Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19X CAR-T in Relapsed/Refractory Large B-Cell Lymphoma
NCT07447726Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Apr 2026
- Primary completion
- Jan 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
A Phase 2 trial of CD19X CAR-T in diffuse large B-cell lymphoma (DLBCL), sponsored by Institute of Hematology and Blood Diseases Hospital. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
CD19X CAR-T
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07447726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07447726.